Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
Celcuity Inc. (CELC) to participate in Cowen’s 44th Annual Health Care Conference with CEO Brian Sullivan scheduled for a fireside chat. Live webcast details provided.
02/28/2024 - 07:05 AM
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in Cowen’s 44th Annual Health Care Conference to be held in Boston on March 4-6, 2024.
Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 2:10 p.m. ET on Wednesday, March 6, 2024. A live webcast of the event will be available using this weblink https://wsw.com/webcast/cowen154/celc/1980218 . Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov . A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is currently enrolling patients. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at Celcuity.com . Follow us on LinkedIn and Twitter .
Contacts:
Celcuity Inc. Brian Sullivan, bsullivan@celcuity.com Vicky Hahne, vhahne@celcuity.com (763) 392-0123
ICR Westwicke Maria Yonkoski, maria.yonkoski@westwicke.com (203) 682-7167
When is Celcuity Inc. participating in Cowen’s 44th Annual Health Care Conference?
Celcuity Inc. (CELC) is participating in Cowen’s 44th Annual Health Care Conference on March 4-6, 2024.
Who is scheduled for a fireside chat at the conference?
Brian Sullivan, the Chief Executive Officer, and Co-founder of Celcuity Inc., is scheduled for a fireside chat at 2:10 p.m. ET on Wednesday, March 6, 2024.
Where can the live webcast of the event be accessed?
The live webcast of the event can be accessed using the weblink https://wsw.com/webcast/cowen154/celc/1980218 or from the Investors section of Celcuity Inc.'s website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.
CELC Rankings
#2062 Ranked by Stock Gains
CELC Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Commercial Services, Miscellaneous Commercial Services, Health Care and Social Assistance, Medical Laboratories
About CELC
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.